AR084886A1 - Proteinas de union a inhibidores de factores de coagulacion - Google Patents

Proteinas de union a inhibidores de factores de coagulacion

Info

Publication number
AR084886A1
AR084886A1 ARP120100166A ARP120100166A AR084886A1 AR 084886 A1 AR084886 A1 AR 084886A1 AR P120100166 A ARP120100166 A AR P120100166A AR P120100166 A ARP120100166 A AR P120100166A AR 084886 A1 AR084886 A1 AR 084886A1
Authority
AR
Argentina
Prior art keywords
seq
presented
cdr sequences
antibody
variable
Prior art date
Application number
ARP120100166A
Other languages
English (en)
Spanish (es)
Inventor
Dittmer Frank Dr
Buchmller Anja Dr
Gerdes Christoph Dr
Tersteegen Adrian Dr
Gnoth Mark Jean Dr
Linden Lars Dr
Harrenga Axel Dr
Grudzinska Joanna Dr
Jeske Mario Dr
Schfer Martina Dr
Birkenfeld Jrg Dr
Paulsen Holger Dr
Finnern Ricarda Dr
Mayer-Bartschmid Anke Dr
Eicker Andrea Dr
Simone Greven
Susanne Steinig
Original Assignee
Bayer Pharma Aktiengellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengellschaft filed Critical Bayer Pharma Aktiengellschaft
Publication of AR084886A1 publication Critical patent/AR084886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP120100166A 2011-01-19 2012-01-18 Proteinas de union a inhibidores de factores de coagulacion AR084886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11151410 2011-01-19

Publications (1)

Publication Number Publication Date
AR084886A1 true AR084886A1 (es) 2013-07-10

Family

ID=45491612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100166A AR084886A1 (es) 2011-01-19 2012-01-18 Proteinas de union a inhibidores de factores de coagulacion

Country Status (7)

Country Link
US (1) US20140050743A1 (enExample)
EP (1) EP2665751A1 (enExample)
JP (1) JP2014506448A (enExample)
CN (1) CN103619883A (enExample)
AR (1) AR084886A1 (enExample)
CA (1) CA2824885A1 (enExample)
WO (1) WO2012098089A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102039189B1 (ko) * 2016-03-23 2019-11-01 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
NL2036011B1 (en) * 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6669937B2 (en) * 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
KR100863113B1 (ko) 2001-06-20 2008-10-13 다이이찌 산쿄 가부시키가이샤 디아민 유도체
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
CA2743496C (en) * 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑

Also Published As

Publication number Publication date
JP2014506448A (ja) 2014-03-17
WO2012098089A1 (en) 2012-07-26
CA2824885A1 (en) 2012-07-26
CN103619883A (zh) 2014-03-05
EP2665751A1 (en) 2013-11-27
US20140050743A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
MX363642B (es) Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
UY33196A (es) Antidotos de anticoagulantes
AR127516A2 (es) VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
AR092005A1 (es) Anticuerpos anti-pcsk9 y uso de los mismos
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
CO6260094A2 (es) Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
RU2012143793A (ru) Биспецифические двухвалентные антитела анти-vegf/анти-ang-2
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
ECSP17005649A (es) Anticuerpos anti-tau humanizados
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
AR095432A1 (es) Proteínas de unión a antígeno
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
RU2014143639A (ru) Регулируемые протеазой антитела
CY1118551T1 (el) Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4
EA201490677A1 (ru) Связывающие антиген cd27l белки

Legal Events

Date Code Title Description
FA Abandonment or withdrawal